{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T09:08:23Z","timestamp":1768208903856,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011447","name":"Science and Technology Department of Henan Province","doi-asserted-by":"publisher","award":["192102310085"],"award-info":[{"award-number":["192102310085"]}],"id":[{"id":"10.13039\/501100011447","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Henan Provincial Commission of Health and Family Planning","award":["SBGJ202102035"],"award-info":[{"award-number":["SBGJ202102035"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Arylsulfatase A (ARSA), a lysosomal enzyme, has been shown to inhibit the aggregation and propagation of \u03b1-synuclein (\u03b1-syn) through its molecular chaperone function. The relationship between ARSA levels and Parkinson\u2019s disease (PD) in the Chinese Han population remains controversial, and few quantitative research studies have investigated the relationship between plasma ARSA levels and PD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>The purpose of this study was to investigate the relationships between ARSA levels and cognitive function in PD patients and to evaluate the association of ARSA and \u03b1-syn levels with nonmotor symptoms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Enzyme-linked immunosorbent assay (ELISA) was used to measure the plasma ARSA and \u03b1-syn levels in 50 healthy controls, 120 PD patients (61 PD patients with no cognitive impairment (PD-NCI) and 59 PD patients with cognitive impairment (PD-CI)). Motor symptoms and nonmotor symptoms (cognitive function, Unified Parkinson\u2019s Disease Rating Scale (UPDRS) score, depression, anxiety, constipation, olfactory dysfunction, sleep disruption, and other symptoms) were assessed with the relevant scales. The Kruskal\u2013Wallis <jats:italic>H<\/jats:italic> test was used for comparison between groups, and <jats:italic>Pearson\/Spearman analysis<\/jats:italic> was used for correlation analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The plasma ARSA concentrations were lower in the PD-CI group than in the PD-NCI group. The plasma \u03b1-syn levels in the PD-CI group were higher than those in the healthy control group, and the plasma ARSA levels were correlated with the Mini-Mental State Examination (MMSE scores) and Hoehn and Yahr (H-Y) stage.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We used a quantitative assessment method to show that low plasma ARSA levels and high \u03b1-syn levels are related to cognitive impairment in PD patients. Plasma ARSA levels gradually decrease with PD progression.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10072-022-06093-w","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T07:02:53Z","timestamp":1651215773000},"page":"4753-4759","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Plasma arylsulfatase A levels are associated with cognitive function in Parkinson\u2019s disease"],"prefix":"10.1007","volume":"43","author":[{"given":"Mingjian","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxue","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5825-1927","authenticated-orcid":false,"given":"Jianjun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhidong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongsheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenxiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"issue":"9","key":"6093_CR1","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1093\/brain\/awz205","volume":"142","author":"JS Lee","year":"2019","unstructured":"Lee JS, Kanai K, Suzuki M, Kim WS, Yoo HS, Fu Y, Kim D, Jung BC et al (2019) Arylsulfatase A, a genetic modifier of Parkinson\u2019s disease, is an \u03b1-synuclein chaperone. Brain 142(9):2845\u20132859. https:\/\/doi.org\/10.1093\/brain\/awz205","journal-title":"Brain"},{"issue":"2","key":"6093_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/mds.23477","volume":"26","author":"SK Song","year":"2011","unstructured":"Song SK, Lee JE, Park H, Sohn YH, Lee JD, Lee PH (2011) The pattern of cortical atrophy in patients with Parkinson\u2019s disease according to cognitive status. Movement Disord 26(2):289\u2013296. https:\/\/doi.org\/10.1002\/mds.23477","journal-title":"Movement Disord"},{"key":"6093_CR3","doi-asserted-by":"publisher","unstructured":"Yoo HS, Lee JS, Chung SJ, Ye BS, Sohn YH, Lee S, Lee PH (2020) Changes in plasma arylsulfatase A level as a compensatory biomarker of early Parkinson\u2019s disease. Sci Rep-Uk 10(1):5567. https:\/\/doi.org\/10.1038\/s41598-020-62536-4","DOI":"10.1038\/s41598-020-62536-4"},{"key":"6093_CR4","doi-asserted-by":"publisher","unstructured":"Pan HX, Wang YG, Zhao YW, Zeng Q, Wang Z, Fang ZH, Zhang Y, Zhou X et al (2022) Evaluating the role of ARSA in Chinese patients with Parkinson\u2019s disease. Neurobiol Aging 109:269\u2013272.\u00a0https:\/\/doi.org\/10.1016\/j.neurobiolaging.2021.08.008","DOI":"10.1016\/j.neurobiolaging.2021.08.008"},{"key":"6093_CR5","doi-asserted-by":"publisher","first-page":"135094","DOI":"10.1016\/j.neulet.2020.135094","volume":"734","author":"Y Ruan","year":"2020","unstructured":"Ruan Y, Zheng R, Lin Z, Gao T, Xue N, Cao J, Tian J, Zhang B et al (2020) Genetic analysis of arylsulfatase A (ARSA) in Chinese patients with Parkinson\u2019s disease. Neurosci Lett 734:135094. https:\/\/doi.org\/10.1016\/j.neulet.2020.135094","journal-title":"Neurosci Lett"},{"issue":"8","key":"6093_CR6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.parkreldis.2013.03.009","volume":"19","author":"Y Compta","year":"2013","unstructured":"Compta Y, Pereira JB, Rios J, Ibarretxe-Bilbao N, Junque C, Bargallo N, Camara A, Buongiorno M et al (2013) Combined dementia-risk biomarkers in Parkinson\u2019s disease: a prospective longitudinal study. Parkinsonism Relat Disord 19(8):717\u2013724. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.03.009","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"6093_CR7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.parkreldis.2014.12.027","volume":"21","author":"C Liu","year":"2015","unstructured":"Liu C, Cholerton B, Shi M, Ginghina C, Cain KC, Auinger P, Zhang J (2015) CSF tau and tau\/Abeta42 predict cognitive decline in Parkinson\u2019s disease. Parkinsonism Relat Disord 21(3):271\u2013276. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.12.027","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"6093_CR8","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K et al (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Movement Disord 30(12):1591\u20131601. https:\/\/doi.org\/10.1002\/mds.26424","journal-title":"Movement Disord"},{"key":"6093_CR9","doi-asserted-by":"publisher","first-page":"579268","DOI":"10.3389\/fneur.2020.579268","volume":"11","author":"KW Park","year":"2020","unstructured":"Park KW, Jo S, Kim MS, Jeon SR, Ryu HS, Kim J, Park YM, Koh SB et al (2020) Genomic Association Study for Cognitive Impairment in Parkinson\u2019s Disease. Front Neurol 11:579268. https:\/\/doi.org\/10.3389\/fneur.2020.579268","journal-title":"Front Neurol"},{"issue":"02","key":"6093_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1017\/S1041610206003772","volume":"19","author":"JM Ringman","year":"2007","unstructured":"Ringman JM, Rodriguez Y, Diaz-Olavarrieta C, Chavez M, Thompson M, Fairbanks L, Paz F, Varpetian A et al (2007) Performance on MMSE sub-items and education level in presenilin-1 mutation carriers without dementia. Int Psychogeriatr 19(02):323. https:\/\/doi.org\/10.1017\/S1041610206003772","journal-title":"Int Psychogeriatr"},{"key":"6093_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3389\/fnins.2019.00369","volume":"13","author":"E Fitzgerald","year":"2019","unstructured":"Fitzgerald E, Murphy S, Martinson HA (2019) Alpha-synuclein pathology and the role of the microbiota in Parkinson\u2019s disease. Front Neurosci 13:369. https:\/\/doi.org\/10.3389\/fnins.2019.00369","journal-title":"Front Neurosci"},{"issue":"Suppl 3","key":"6093_CR12","doi-asserted-by":"publisher","first-page":"S143","DOI":"10.1016\/S1353-8020(09)70802-8","volume":"15","author":"E Angot","year":"2009","unstructured":"Angot E, Brundin P (2009) Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson\u2019s disease. Parkinsonism Relat Disord 15(Suppl 3):S143\u2013S147. https:\/\/doi.org\/10.1016\/S1353-8020(09)70802-8","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"6093_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00441-018-2814-1","volume":"373","author":"JA Steiner","year":"2018","unstructured":"Steiner JA, Quansah E, Brundin P (2018) The concept of alpha-synuclein as a prion-like protein: ten years after. Cell Tissue Res 373(1):161\u2013173. https:\/\/doi.org\/10.1007\/s00441-018-2814-1","journal-title":"Cell Tissue Res"},{"issue":"48","key":"6093_CR14","doi-asserted-by":"publisher","first-page":"33855","DOI":"10.1074\/jbc.274.48.33855","volume":"274","author":"MC Bennett","year":"1999","unstructured":"Bennett MC, Bishop JF, Leng Y, Chock PB, Chase TN, Mouradian MM (1999) Degradation of alpha-synuclein by proteasome. J Biol Chem 274(48):33855\u201333858. https:\/\/doi.org\/10.1074\/jbc.274.48.33855","journal-title":"J Biol Chem"},{"key":"6093_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.nbd.2018.04.015","volume":"116","author":"H Wang","year":"2018","unstructured":"Wang H, Atik A, Stewart T, Ginghina C, Aro P, Kerr KF, Seibyl J, Jennings D et al (2018) Plasma alpha-synuclein and cognitive impairment in the Parkinson\u2019s associated risk syndrome: a pilot study. Neurobiol Dis 116:53\u201359. https:\/\/doi.org\/10.1016\/j.nbd.2018.04.015","journal-title":"Neurobiol Dis"},{"key":"6093_CR16","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1038\/ncomms5755","volume":"5","author":"EJ Bae","year":"2014","unstructured":"Bae EJ, Yang NY, Song M, Lee CS, Lee JS, Jung BC, Lee HJ, Kim S et al (2014) Glucocerebrosidase depletion enhances cell-to-cell transmission of alpha-synuclein. Nat Commun 5:4755. https:\/\/doi.org\/10.1038\/ncomms5755","journal-title":"Nat Commun"},{"issue":"17","key":"6093_CR17","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N Engl J Med 361(17):1651\u20131661. https:\/\/doi.org\/10.1056\/NEJMoa0901281","journal-title":"N Engl J Med"},{"issue":"9","key":"6093_CR18","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1212\/01.wnl.0000176987.47875.28","volume":"65","author":"J Aharon-Peretz","year":"2005","unstructured":"Aharon-Peretz J, Badarny S, Rosenbaum H, Gershoni-Baruch R (2005) Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype-genotype correlation. Neurology 65(9):1460\u20131461. https:\/\/doi.org\/10.1212\/01.wnl.0000176987.47875.28","journal-title":"Neurology"},{"issue":"9","key":"6093_CR19","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1093\/brain\/awv179","volume":"138","author":"RN Alcalay","year":"2015","unstructured":"Alcalay RN, Levy OA, Waters CH, Fahn S, Ford B, Kuo S, Mazzoni P, Pauciulo MW et al (2015) Glucocerebrosidase activity in Parkinson\u2019s disease with and without GBA mutations. Brain 138(9):2648\u20132658. https:\/\/doi.org\/10.1093\/brain\/awv179","journal-title":"Brain"},{"issue":"2","key":"6093_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10545-007-0540-z","volume":"30","author":"C Sevin","year":"2007","unstructured":"Sevin C, Aubourg P, Cartier N (2007) Enzyme, cell and gene-based therapies for metachromatic leukodystrophy. J Inherit Metab Dis 30(2):175\u2013183. https:\/\/doi.org\/10.1007\/s10545-007-0540-z","journal-title":"J Inherit Metab Dis"},{"issue":"9","key":"6093_CR21","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/mt.2015.106","volume":"23","author":"J Doerr","year":"2015","unstructured":"Doerr J, Bockenhoff A, Ewald B, Ladewig J, Eckhardt M, Gieselmann V, Matzner U, Brustle O et al (2015) Arylsulfatase A overexpressing human iPSC-derived neural cells reduce CNS sulfatide storage in a mouse model of metachromatic leukodystrophy. Mol Ther 23(9):1519\u20131531. https:\/\/doi.org\/10.1038\/mt.2015.106","journal-title":"Mol Ther"},{"issue":"10","key":"6093_CR22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/brainsci10100713","volume":"10","author":"E Angelopoulou","year":"2020","unstructured":"Angelopoulou E, Paudel YN, Villa C, Piperi C (2020) Arylsulfatase A (ASA) in Parkinson\u2019s disease: from pathogenesis to biomarker potential. Brain Sci 10(10):713. https:\/\/doi.org\/10.3390\/brainsci10100713","journal-title":"Brain Sci"},{"issue":"4","key":"6093_CR23","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ymthe.2005.06.438","volume":"12","author":"T Luca","year":"2005","unstructured":"Luca T, Givogri MI, Perani L, Galbiati F, Follenzi A, Naldini L, Bongarzone ER (2005) Axons mediate the distribution of arylsulfatase a within the mouse hippocampus upon gene delivery. Mol Ther 12(4):669\u2013679. https:\/\/doi.org\/10.1016\/j.ymthe.2005.06.438","journal-title":"Mol Ther"},{"issue":"1","key":"6093_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0022-510X(02)00159-4","volume":"201","author":"JS Meyer","year":"2002","unstructured":"Meyer JS, Xu G, Thornby J, Chowdhury M, Quach M (2002) Longitudinal analysis of abnormal domains comprising mild cognitive impairment (MCI) during aging. J Neurol Sci 201(1):19\u201325. https:\/\/doi.org\/10.1016\/S0022-510X(02)00159-4","journal-title":"J Neurol Sci"},{"issue":"6","key":"6093_CR25","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/ana.24664","volume":"79","author":"I Guella","year":"2016","unstructured":"Guella I, Evans DM, Szu-Tu C, Nosova E, Bortnick SF, Goldman JG, Dalrymple-Alford JC, Geurtsen GJ et al (2016) \u03b1-synuclein genetic variability: a biomarker for dementia in Parkinson disease. Ann Neurol 79(6):991\u2013999. https:\/\/doi.org\/10.1002\/ana.24664","journal-title":"Ann Neurol"},{"key":"6093_CR26","doi-asserted-by":"publisher","first-page":"616357","DOI":"10.3389\/fnagi.2020.616357","volume":"12","author":"H Murakami","year":"2020","unstructured":"Murakami H, Ono K, Shiraishi T, Umehara T, Omoto S, Iguchi Y (2020) Mini Review: Correlations of cognitive domains with cerebrospinal fluid alpha-synuclein levels in patients with Parkinson\u2019s disease. Front Aging Neurosci 12:616357. https:\/\/doi.org\/10.3389\/fnagi.2020.616357","journal-title":"Front Aging Neurosci"},{"issue":"10","key":"6093_CR27","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/jnnp-2016-314857","volume":"88","author":"C Lin","year":"2017","unstructured":"Lin C, Yang S, Horng H, Yang C, Chieh J, Chen H, Liu B, Chiu M (2017) Plasma \u03b1-synuclein predicts cognitive decline in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 88(10):818\u2013824. https:\/\/doi.org\/10.1136\/jnnp-2016-314857","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06093-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-06093-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06093-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T13:15:39Z","timestamp":1659532539000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-06093-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["6093"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-06093-w","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]},"assertion":[{"value":"24 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the Ethics Committee of the Henan Provincial People\u2019s Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"All participants agreed to participate and signed an informed consent document.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}